Johan Lundkvist is chief scientific officer and co-founder of Sinfonia Biotherapeutics AB, a clinical-stage company based in Sweden and the U.S. Dr. Lundkvist is a neurobiologist and cell biologist by training and has over 20 years of research in academia and industry on neurodegenerative disorders. He has published approximately 50 publications in peer-reviewed journals and became associate professor of cell biology at the Karolinska Institute in 2005. He has held various scientific leading positions at AstraZeneca (2004-2012) and was a member of the strategy team for the disease-modifier portfolio. Dr. Lundkvist is a co-founder of AlzeCure Foundation and AlzeCure Pharma AB, a biotech company listed on the Swedish Nasdaq First North. More recently, Dr. Lundkvist has been a driver for cell-based therapies to treat genetically defined neurodegenerative diseases within Sinfonia, leveraging the strengths of the company’s proprietary gene therapy device called encapsulated cell-based biodelivery, ECB.